Evidence map›Paper›PMID 27091610›Full record

ArticleNeuro-oncology2016

COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors.

Denise D Correa, Jaya Satagopan, Kenneth Cheung, Arshi K Arora, Maria Kryza-Lacombe, Youming Xu, Sasan Karimi, John Lyo, Lisa M DeAngelis, Irene Orlow

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Denise D CorreaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.) corread@mskcc.org.
Jaya SatagopanDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
Kenneth CheungDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
Arshi K AroraDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
Maria Kryza-LacombeDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
Youming XuDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
Sasan KarimiDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
John LyoDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
Lisa M DeAngelisDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).
Irene OrlowDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (D.D.C., M.K.-L., L.M.D.); Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York (J.S., K.C., A.K.A., Y.X., I.O.); Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York (S.K., J.L.); Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York (D.D.C., L.M.D.).

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Clinical and Translational Science CenterKL2TR000458 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$2.1M
Study of exposures and biomarkers in cancer epidemiologyR01CA197402 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SATAGOPAN, JAYA M · 2016 to 2019
$1.6M
STUDY OF EXPOSURES, BEHAVIORS, AND BIOMARKERS IN CANCER EPIDEMIOLOGYR01CA137420 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SATAGOPAN, JAYA M · 2009 to 2012
$1.6M
NCATS NIH HHS KL2 TR000458NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA137420NCI NIH HHS R01 CA197402
6 · The paper itself

Abstract

backgroundCognitive dysfunction is common among patients with brain tumors and can be associated with the disease and treatment with radiotherapy and chemotherapy. However, little is known about genetic risk factors that may moderate the vulnerability for developing cognitive dysfunction. In this study, we examined the association of single nucleotide polymorphisms (SNPs) in the catechol-O-methyl transferase (COMT), brain-derived neurotrophic factor (BDNF), and dystrobrevin-binding protein 1 (DTNBP1) genes with cognitive functions and neuroimaging outcomes in patients with brain tumors.

methodsOne hundred and fifty patients with brain tumors completed neuropsychological tests of attention, executive functions, and memory and were genotyped for polymorphisms in the COMT, BDNF, and DTNBP1 genes. Ratings of white matter (WM) abnormalities on magnetic resonance imaging scans were performed.

resultsMultivariate regression shrinkage analyses, adjusted for age, education, treatment type, time since treatment completion, and tumor location, indicated a significant association between the COMT SNP rs4680 (Val158Met) and memory with lower scores in delayed recall (P < .01) among homozygotes (valine/valine). Additional COMT, BDNF and DTNBP1 SNPs were significantly associated with attention, executive functions, and memory scores.

conclusionThis is the first study to suggest that known and newly described polymorphisms in genes associated with executive and memory functions in healthy individuals and other clinical populations may modulate cognitive outcome in patients with brain tumors.

Indexed as

AdultAgedAged, 80 and overBrain-Derived Neurotrophic FactorBrain NeoplasmsCatechol O-MethyltransferaseCognition DisordersDysbindinDystrophin-Associated ProteinsFemaleGenetic Predisposition to DiseaseGenotypeHumansMagnetic Resonance ImagingMaleMiddle AgedBDNF protein, humanBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseCOMT protein, humanDTNBP1 protein, humanDysbindinDystrophin-Associated ProteinsBDNFbrain tumors, cognitiveCOMTDTNBP1

Identifiers

PMID27091610
PMCPMC5035520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.